Dermira, Inc. (NASDAQ:DERM) Files An 8-K Financial Statements and Exhibits

(d) Exhibits.

Dermira, Inc. ExhibitEX-99.1 2 derm-ex991_7.htm EX-99.1 derm-ex991_7.htm   Exhibit 99.1   Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis – Qbrexza is the first FDA-approved,…To view the full exhibit click here
About Dermira, Inc. (NASDAQ:DERM)
Dermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.